Beyond Meat’s stock continues to skyrocket and even the most optimistic Wall Street analysts are lagging far behind.
Shares of the alternative meat company jumped more than 600% from the initial public offering price of $25 a share during intraday trade Monday, hitting a high of $186.43 a share. It finished the day up 21.2% at $168.10, up about 570% from its IPO price. Beyond Meat reported first-quarter results Thursday that were stronger than expected, telling investors that it expects revenue to more than double over the next year.
There are eight Wall Street firms covering Beyond Meat’s stock and, after the company’s earnings, five of them raised their price targets.
But even the highest price target – Credit Suisse at $125 a share – was immediately outpaced when Beyond Meat’s stock began tradingMonday. Beyond Meat shares soared toward its third best day of trading ever, climbing more than 25% at one point.
Beyond Meat’s stock is over 65% above the average Wall Street 12-month price target of $103.85 a share.
Beyond Meat “issued revenue guidance for 2019 that exceeded our estimate by 11% due to distribution gains and velocity growth,” Credit Suisse analyst Robert Moskow told investors Friday. His firm’s price target nearly doubled, as Credit Suisse raised it from $70 a share to $125 a share.
“At some point, the extraordinary revenue and profit potential embedded in [Beyond Meat] will be priced in,” J.P. Morgan analyst Ken Goldman told investors Friday. Goldman’s forecast is $120.
But “as long as Street forecasts fail to properly reflect BYND’s remarkable potential, we remain Overweight,” Goldman added.
Here is the full list of analysts covering Beyond Meat’s stock and their price targets in descending order:
I hope you found this helpful, have a successful day!
Stock Market Resilient Amid Soaring Crude Oil Prices, Fed Rate Cut, China Trade News; Microsoft, Adobe, FedEx, GM, Roku In Focus: Weekly Review
China delegation’s sudden departure highlights trade and tariffs as main movers of markets
The Fed pumps another $75 billion into markets — its 3rd straight daily injection